Adial Pharmaceuticals Inc ADIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADIL is a good fit for your portfolio.
News
-
Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
-
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
-
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
-
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
-
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
-
Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20
-
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
-
Adial Pharma to Conduct Two More AD04 Phase 3 Trials After Regulatory Feedback
Trading Information
- Previous Close Price
- $1.71
- Day Range
- $1.62–1.76
- 52-Week Range
- $0.77–14.00
- Bid/Ask
- $1.73 / $1.82
- Market Cap
- $7.01 Mil
- Volume/Avg
- 722 / 7.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.adialpharma.com
Valuation
Metric
|
ADIL
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.70 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ADIL
|
---|---|
Quick Ratio | 4.33 |
Current Ratio | 4.90 |
Interest Coverage | — |
Quick Ratio
ADIL
Profitability
Metric
|
ADIL
|
---|---|
Return on Assets (Normalized) | −125.03% |
Return on Equity (Normalized) | −181.77% |
Return on Invested Capital (Normalized) | −181.75% |
Return on Assets
ADIL
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vvzjdvmxx | Xgjp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dffftpwq | Xbrfh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hlxhzgx | Mxcywxq | $97.8 Bil | |
MRNA
| Moderna Inc | Kctxdkby | Trcsw | $38.8 Bil | |
ARGX
| argenx SE ADR | Vsgdplll | Jrhbb | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Zppnjvlh | Qwmqd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Whkgwlyc | Cmqwdy | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fhnmhlsdr | Vqcwypw | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cqhvdbbj | Ptzxb | $12.5 Bil | |
INCY
| Incyte Corp | Cdfmwcj | Ynzfjn | $11.5 Bil |